Journal
CURRENT PROBLEMS IN PEDIATRIC AND ADOLESCENT HEALTH CARE
Volume 48, Issue 2, Pages 50-62Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cppeds.2017.12.001
Keywords
-
Categories
Funding
- NIMH, United States [MH106037, MH105464, MH107378, MH097818]
- NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH097818, R01MH105464, R01MH107378, K23MH106037] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The tolerability of antidepressants is poorly characterized in children and adolescents with depressive and anxiety disorders. Among adverse events that affect the tolerability of antidepressants in youth is activation, a cluster of symptoms that represent a hyperarousal event characterized by impulsivity, restlessness, and/or insomnia. This cluster of symptoms was first identified as a side effect of selective serotonin and selective serotonin norepinephrine inhibitors (SSRIs and SSNRIs) in the early 1990s; however, activation remains poorly characterized in terms of prevalence, risk factors, and pathophysiology. This article describes the pathophysiology of antidepressant-related activation, predictors of activation and its clinical management in youth with depressive and anxiety disorders who are treated with antidepressant medications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available